About this trial
This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.
Eligibility criteria
Qualifiers
Men and women aged 19-70 years who underwent endoscopic resection for high-grade adenoma or early gastric cancer (category 4 [non-invasive high grade neoplasm] or category 5 [invasive neoplasia] according to the Vienna classification of gastrointestinal epithelial neoplasia [Schlemper RJ, et al. Gut 2000;47:251-255.])
Final pathological results after endoscopic resection met the absolute or expanded criteria according to the Japanese Gastric Cancer Treatment guideline 2014 (version 4)
Patients who had negative H. pylori status or those who eradicated H. pylori status
Willingness to sign an informed consent form
Disqualifiers
Patients who received aspirin for the secondary prevention of cardiovascular diseases or cerebrovascular diseases
Regular aspirin uses (more than 3 times a week) with 2 months before screening visit
Patients who used anticoagulants or antiplatelet drugs for therapeutic purpose
Previous gastrectomy history
Trial design
Treatments tested in this trial
- Aspirin 100mg
- Placebo oral tablet
Treatment groups
Sponsors and collaborators
National Cancer Center, Korea
Lead sponsor
Incheon St.Mary's Hospital/The Catholic University
Collaborator
Kosin University Gospel Hospital
Collaborator
Pusan National University Hospital
Collaborator
SMG-SNU Boramae Medical Center
Collaborator
Chonnam National University Hospital
Collaborator
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Collaborator
Chilgok Kyungpook National University
Collaborator
Hallym University Medical Center
Collaborator
Asan Medical Center
Collaborator
Seoul National University Bundang Hospital
Collaborator
Severance Hospital
Collaborator
Samsung Medical Center
Collaborator